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Inpatient Oral Anticoagulation Management by Clinical 
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Abstract
Background: Warfarin prescription for anticoagulation after car-
diac surgery has always been a challenge for junior medical staff.
Methods:  A prospective study was carried out to assess the quality 
of anticoagulation control by junior doctors compared with clinical 
pharmacists at South Manchester University hospitals NHS Trust. 
The junior medical staff prescribed warfarin for 50 consecutive pa-
tients from April to September 2006 (group A, n = 50) and experi-
enced clinical pharmacists dosed 46 consecutive patients between 
February and May 2007 (group B, n = 46).
Results:  In group A, 9 (18%) patients discharge was delayed be-
cause of lack of attainment of therapeutic International Normalised 
Ratio (INR) compared to 3 (6.5%) in group B. The total number 
of bed days resulting from the delay in group A was 21 compared 
to 4 in group B. Extrapolated over a year this would amount to 
approximately £15,750 extra cost incurred in group A opposed to 
£3000 in group B.
Conclusions:  The pharmacists were significantly better than junior 
doctors in achieving therapeutic INR, resulting in fewer discharge 
delays. The clinical pharmacists with experience in outpatient an-
ticoagulation clinic can play an important role in inpatient oral an-
ticoagulation management in post cardiac surgery patients thereby 
providing improved cost effective quality of care.
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Introduction
The safe management of oral anticoagulation in patients is a 
challenge in both ward and community. Sub-therapeutic and 
supra-therapeutic INR (International Normalised Ratio) can 
be hazardous to the patient. National Patient Safety Agency 
(NPSA) alert 18 was recently published to ensure safer pre-
scribing,  dispensing  and  administration  of  anticoagulants. 
We designed a study to assess the safety of anticoagulation 
management in cardiothoracic ward by clinical pharmacists 
with experience in anticoagulation clinics. This study was to 
assess the safety and efficiency of inpatient oral anticoagula-
tion management by experienced clinical pharmacists com-
pared with junior doctors following cardiac surgery.
 
Patients and Methods
A prospective study was carried out to assess the quality of 
anticoagulation  control  by  junior  doctors  compared  with 
clinical  pharmacists  at  South  Manchester  University  hos-
pitals NHS Trust. The junior medical staff prescribed war-
farin for 50 consecutive patients from April to September 
2006 (group A, n = 50) and experienced clinical pharmacists 
dosed 46 consecutive patients between Feb and May 2007 
(group B, n = 46). There were six senior house officers in 
the department and the oncall doctor would do the prescrib-
ing of warfarin for all the patients on the given day. In the 
pharmacist group the prescribing was shared by two clinical 
pharmacists with experience in managing out patient antico-
agulation clinic.
 
Results
In group A, 10 patients INR was above 5 where as only 2 
patients attained high INR in group B. In group A, 9 (18%) 
patients discharge was delayed because of lack of attainment 
of therapeutic INR compared to 3 (6.5%) in group B. The 
total number of bed days resulting from the delay in group A 
was 21 compared to 4 in group B. Extrapolated over a year 
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this would amount to approximately £15,750 extra cost in-
curred in group A opposed to £3000 in group B, Figures 1-3.
Discussion
  
In our pilot study the pharmacists were significantly better 
than junior doctors in achieving therapeutic INR, resulting 
in  fewer  discharge  delays.  The  clinical  pharmacists  with 
experience in out patient anticoagulation clinic can play an 
important role in inpatient oral anticoagulation management 
in post cardiac surgery patients thereby providing improved 
cost effective quality of care. The junior doctors in the car-
diothoracic department are more familiar than junior doctors 
in other specialties with warfarin prescription because of the 
patient population. Despite this there was significant differ-
ence compared with pharmacist management. Therefore the 
difference is likely to be greater if the study had included 
junior doctors in other specialties where warfarin use is less 
common. The results of our study are of interest in keeping 
with the recently published National Patient Safety Agency 
(NPSA) alert 18 [1] which identifies anticoagulants as one 
of four high risk medications that require multidisciplinary 
interventions to reduce the harm to patients in hospitals.
Warfarin administration is a challenge to the junior medical 
staff. The challenge is to attain the therapeutic range of INR 
with lowest effective dose. The interaction of warfarin with 
several other commonly used medications and variability in 
response from different patients makes it very difficult to at-
tain and maintain therapeutic range of INR. The lower than 
normal INR would predispose the patients to thrombotic risk 
and higher than therapeutic range expose the patients to po-
tentially life threatening bleeding complications. Landefeld 
et al, in their meta-analysis showed warfarin administration 
is associated with a 0.6% annual risk of bleeding-related 
death, a 3% annual risk of a major bleeding event, and a 
9.6% annual risk of a major or minor bleeding event, with 
the risk being highest at the start of therapy [2].
Several other studies have showed the effectiveness of clini-
cal pharmacists in out patient [3-7] and inpatient [8, 9] an-
ticoagulation management. Although the out patient service 
is largely run by clinical pharmacists in UK, their role in 
inpatient anticoagulation is limited. Based on our study and 
several other studies in the literature it appears that clinical 
pharmacists’  anticoagulation  management  is  safer  for  pa-
tients and more cost effective for hospitals.
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